Esketamine (Spravato®). HTA ID: 19055

Assessment Status Assessment process complete
HTA ID 19055
Drug Esketamine
Brand Spravato®
Indication In combination with a SSRI or SNRI is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current depressive episode
Assessment Process
Rapid review commissioned 16/12/2019
Rapid review completed 10/02/2020
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of esketamine compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 10/02/2020
Pre-submission consultation with Applicant 30/03/2020
Full submission received from Applicant 10/08/2020
Preliminary review sent to Applicant 09/11/2020
NCPE assessment re-commenced 08/12/2020
Follow-up to preliminary review sent to Applicant 14/12/2020
NCPE assessment re-commenced 18/12/2020
Factual accuracy sent to Applicant 11/02/2021
NCPE assessment re-commenced 18/02/2021
NCPE assessment completed 09/03/2021
NCPE assessment outcome The NCPE recommends that esketamine (Spravato®) not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments. *

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations January 2022.